Calidi Biotherapeutics, Inc. (CLDI) News
Track canonical SquawkNews coverage tagged to CLDI, Calidi Biotherapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Calidi Biotherapeutics Received Notice of Noncompliance
On September 21, 2026, the company received a notice from NYSE American that it is not in compliance with Section 1003(a)(ii) due to stockholders' equity of $3.1 million versus the $4.0 million requirement and losses in
NEWS | Sep 25, 2026, 09:35 PM UTC
L
Calidi Biotherapeutics, Inc. (CLDI) Gets NYSE American Equity Deficiency Notice
Calidi Biotherapeutics received an NYSE American notice for non-compliance with stockholders’ equity requirements and must submit a plan by Oct. 21, 2026 to regain compliance by Mar. 21, 2028, or face potential delisting
NEWS | Sep 25, 2026, 09:02 PM UTC
L
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announ
NEWS | Sep 25, 2026, 09:02 PM UTC
M
Calidi Biotherapeutics raises $1.2M via registered direct offering
Calidi Biotherapeutics sold 1,025,640 common shares at $1.17 per share, generating about $1.2 million in gross proceeds. The offering closed September 21, 2026.
EQUITY | Sep 22, 2026, 09:03 PM UTC
L
CLDI - Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
CLDI - Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
NEWS | Sep 17, 2026, 01:11 PM UTC
L
Calidi Biotherapeutics to participate in H.C. Wainwright 28th conference
Calidi Biotherapeutics Inc. (NYSE American: CLDI) said it will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 08, 2026, 12:07 PM UTC
L
CLDI - Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
CLDI - Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 08, 2026, 12:00 PM UTC
L
Calidi Biotherapeutics reports Q2 2026 financial results
Calidi Biotherapeutics (CLDI) reports its second quarter 2026 financial results and recent business highlights.
EARNINGS | Aug 13, 2026, 08:30 PM UTC
L
CSAI, NEXR, CLDI, OFAL Split
CSAI, NEXR, CLDI, OFAL undergo reverse stock splits
EQUITY | Jul 30, 2026, 09:19 PM UTC
M
CSAI, NEXR, CLDI, OFAL Split
Stock splits for CSAI, NEXR, CLDI, OFAL
EQUITY | Jul 30, 2026, 02:56 PM UTC
L
CLDI - Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Asso
CLDI - Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
EQUITY | Jul 27, 2026, 12:00 PM UTC
H
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Crown Holdings Inc (NYSE: CCK ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY26 adjusted EPS guidance above estimates. Cro
EARNINGS | Jul 21, 2026, 09:11 AM UTC
M
CLDI Presents T-Cell Data
Calidi Biotherapeutics Presents Data On Its Approach Of Simultaneously Activating T-cells While Inducing Expression Of T-Cell Engagers Specifically In Situ In Tumor Microenvironment
EQUITY | Jun 24, 2026, 12:07 PM UTC
M
CLDI Presents CLD-501 Data
Calidi Biotherapeutics presents new data on CLD-501, its in situ T-cell engager candidate targeting TROP-2
EQUITY | Jun 24, 2026, 12:00 PM UTC
L
CLDI Appoints Corsee Sanders
Calidi Biotherapeutics appoints Corsee Sanders, Ph.D., to its Board of Directors, bringing over three decades of biopharmaceutical development experience
EQUITY | Jun 23, 2026, 12:01 PM UTC